COMPANY:

Renovaro Biosci

"Renovaro Inc...today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro’s deep learning and ML programs with Nebul’s high-performance computing (“HPC”) built on the latest platform to accelerate biomarker discovery and next-generation diagnostics."

"Renovaro Biosciences Inc....today announced that it has advanced the first tranche of financing to Predictive Oncology, Inc...to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States....By combining the capabilities of Predictive Oncology, BioSymetrics and RenovaroCube we will have a solid AI stack and an end-to-end solution for biomarker discovery and validation for precision medicine."

"Renovaro Biosciences Inc...today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro’s data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas."

"On February 13th this year (2024), Cyclomics announced that it had entered in a binding LOI with Renovaro/GEDiCube regarding the acquisition of Cyclomics by GEDiCube/Renovaro. Herewith, Cyclomics would like to state that discussions with Renovaro/GEDiCube have stopped earlier this year and that an acquisition will not take place. Cyclomics remains operating as a fully independent company and there is no change in shareholders nor control of the company."

"RenovaroCube...is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024...This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients."

"PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions."

"PersonalAIze...has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform...The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients."

"RenovaroCube...is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024...One presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube’s current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes....A second study demonstrated the Cube platform’s ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood..."

"RenovaroCube...proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer."

"Renovaro Inc...and Cyclomics...proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy."

"GEDi Cube Intl Ltd...and a wholly owned subsidiary of Renovaro Inc...announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics...Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement...Upon closing, the combined companies will aim to accelerate entry into the cancer monitoring market and gain access to integrating whole genome data into GEDiCube’s AI/Machine Learning platform."